Evotec SE (NASDAQ:EVO) Q3 2023 Earnings Call Transcript November 11, 2023 Werner Lanthaler: Welcome to our — good morning. Good afternoon. Welcome to our Q3 Call. Resilient into the Future of Biopharma R&D. That’s how we titled this presentation, which we have uploaded to the Internet and you are welcome to join this call also […]
PARTNERSHIP TO ACCELERATE DEWPOINT’S LEADING ONCOLOGY PIPELINE PROGRAMS TO INVESTIGATIONAL NEW DRUG APPLICATIONS COLLABORATION LEVERAGES EVOTEC’S FULLY INTEGRATED, CLINICAL-ENABLING INDIGO CAPABILITY PLATFORMAGREEMENT IS BASED ON A RISK-SHARING ARRANGEMENT FOLLOWED BY MILESTONE AND ROYALTY PAYMENTS TO EVOTEC BASED ON SUCCESS OF OVERALL PROGRAMS HAMBURG, Germany and BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) an
Many investors define successful investing as beating the market average over the long term. But in any portfolio...